Several potent MCL1-specific inhibitors are currently being scrutinized in clinical trials for the treatment of MM and NHL, and selective BCLxL inhibitors have been designed showing significant anti-tumor activity both in vitro and in vivo. The gene discussed is MCL1; the disease is non-Hodgkin lymphoma.